292 related articles for article (PubMed ID: 15926761)
1. Budget impact of tegaserod on a managed care organization formulary.
Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ
Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
Ariza JG; Martínez JA
Rev Gastroenterol Peru; 2006; 26(1):77-9. PubMed ID: 16622489
[TBL] [Abstract][Full Text] [Related]
5. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
7. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
8. Review article: tegaserod -- the global experience.
Chey WD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
[TBL] [Abstract][Full Text] [Related]
9. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
10. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal illness in managed care: healthcare utilization and costs.
Lim D; Farup C; Lawrence BJ; Sorrell L; Dubois RW; Zeldis JB
Am J Manag Care; 1997 Dec; 3(12):1859-72. PubMed ID: 10178475
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
15. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.
Dorn SD; Farley JF; Hansen RA; Shah ND; Sandler RS
Gastroenterology; 2009 Aug; 137(2):518-24, 524.e1-2. PubMed ID: 19445943
[TBL] [Abstract][Full Text] [Related]
16. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
[TBL] [Abstract][Full Text] [Related]
17. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
Khoshoo V; Armstead C; Landry L
Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
20. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
